PTC completes 60 million financing round

NJBIZ STAFF//March 8, 2013//

Listen to this article

PTC Therapeutics Inc., of South Plainfield, on Thursday announced the completion of a $60 million round of financing, led by Brookside Capital Partners Fund L.P.According to an announcement from PTC, proceeds from the financing will support continued development of Ataluren, a treatment for patients with muscular dystrophy and cystic fibrosis. The drug is in phase 3 trials.